What did @genxmovement actually say?
She said she's been prescribed Testogel, a testosterone gel, as part of her menopause treatment at age 54, after six years of symptoms. She described it as "off-licence" for women and asked her audience for honest experiences with side effects and timelines. She joked she wouldn't "grow a dick by 9pm," which is actually doing more work than it might seem, because it's addressing a real fear many women have about testosterone therapy.
To be clear: this is not a medical claims video. She's not telling anyone to take anything. She's sharing a personal experience and crowdsourcing peer support. That context matters when fact-checking it.
Does the science back this up?
Mostly, yes. Testosterone does have a legitimate evidence base for postmenopausal women, particularly for low libido, and the off-label prescribing reality she describes is accurate. But the evidence gets thinner quickly once you move beyond sexual function.
The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in the Journal of Clinical Endocrinology and Metabolism and co-authored by researchers including Susan Davis, is the most cited document in this space. It concluded there is "high-quality evidence" that testosterone improves sexual function in postmenopausal women, specifically desire, arousal, and orgasm. That's a meaningful finding.
However, the same statement explicitly noted insufficient evidence to support testosterone for mood, cognitive function, energy, or bone density in women. Those are the "feel a little bit normal" benefits she's hoping for, and the honest answer is: the trial data simply doesn't yet confirm them, even if many women report them anecdotally. That gap between clinical evidence and lived experience is real, and it's not nothing, but it's not proof either.
What did they get wrong (or right)?
She got the off-licence status right. Testogel is licensed in the UK for men, and prescribing it to women is indeed off-label, which she correctly called "off-licence." This isn't fringe medicine, it's common practice in menopause clinics, but it does mean the product's dosing and safety data in women comes from research, not the product license itself.
The virilisation fear, the "grow a dick" joke, is worth taking seriously rather than just laughing off. At physiological doses used in women's hormone therapy, clinically significant virilisation (clitoral enlargement, voice deepening, facial hair beyond mild) is uncommon but not impossible, particularly with incorrect dosing or prolonged high-dose use. Davis et al. (2019) found that when blood levels were maintained within the normal female physiological range, androgenic side effects were rare. The joke dismisses a real risk, even if that risk is low at appropriate doses.
What she got right: being excited but asking for honest side effects, not just success stories. That's a better instinct than most wellness content.
What should you actually know?
Testosterone for perimenopausal and postmenopausal women is a legitimate, evidence-supported treatment, but it comes with important qualifications most TikTok comment sections won't give you.
- The strongest evidence is for hypoactive sexual desire disorder, not general menopause symptoms like fatigue or brain fog, despite what many online communities claim.
- Testosterone is almost always prescribed alongside oestrogen in menopause treatment, not as a standalone. If she's only on Testogel with no oestrogen therapy, that's worth a conversation with her prescriber.
- Blood levels should be monitored. The goal is to stay within the normal female physiological range. The British Menopause Society recommends checking total testosterone before starting and periodically after.
- Timing expectations matter. Some women report changes in libido within weeks; broader wellbeing effects, if they occur, often take three to six months. Anyone expecting dramatic results in days is likely to be disappointed.
- Crowdsourcing symptoms from TikTok comments is fine for community support, but it's not a substitute for monitoring with your prescribing clinician.
The Wierman et al. (2014) Endocrine Society guidelines offer a more conservative counterpoint to Davis et al., recommending against testosterone use in women outside of clinical trials except for specific sexual dysfunction indications. Both documents are worth knowing exist.
Is there anything missing from this conversation?
Yes. Nobody in this video mentions cardiovascular risk, polycythaemia (raised red blood cell count, a known risk with testosterone therapy), or the lack of long-term safety data in women, particularly regarding breast cancer risk. The Davis (2019) consensus statement explicitly flagged insufficient data on breast cancer outcomes. That's not a reason to avoid testosterone therapy, but it is a reason to have an informed conversation with a clinician rather than relying on comment sections, however well-meaning.
She's sharing her day one. That's fine. But anyone watching and thinking about starting testosterone themselves should know that the evidence is real but narrower than the wellness internet suggests, and that monitoring matters.